HRP20110198T1 - Indikacija doziranja progesterona u liječenju traumatske ozljede mozga - Google Patents

Indikacija doziranja progesterona u liječenju traumatske ozljede mozga Download PDF

Info

Publication number
HRP20110198T1
HRP20110198T1 HR20110198T HRP20110198T HRP20110198T1 HR P20110198 T1 HRP20110198 T1 HR P20110198T1 HR 20110198 T HR20110198 T HR 20110198T HR P20110198 T HRP20110198 T HR P20110198T HR P20110198 T1 HRP20110198 T1 HR P20110198T1
Authority
HR
Croatia
Prior art keywords
progesterone
administered
treatment
infusion
hour
Prior art date
Application number
HR20110198T
Other languages
English (en)
Croatian (hr)
Inventor
W. Hoffman Stuart
L. Kellerman Arthur
G. Stein Donald
W. Wright David
W. Lowery-North Douglas
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of HRP20110198T1 publication Critical patent/HRP20110198T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HR20110198T 2005-03-24 2011-03-17 Indikacija doziranja progesterona u liječenju traumatske ozljede mozga HRP20110198T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
HRP20110198T1 true HRP20110198T1 (hr) 2011-04-30

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20110198T HRP20110198T1 (hr) 2005-03-24 2011-03-17 Indikacija doziranja progesterona u liječenju traumatske ozljede mozga
HRP20120688TT HRP20120688T1 (hr) 2005-03-24 2012-08-30 Re“im doziranja u liječenju traumatske ozljede mozga progesteronom

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20120688TT HRP20120688T1 (hr) 2005-03-24 2012-08-30 Re“im doziranja u liječenju traumatske ozljede mozga progesteronom

Country Status (16)

Country Link
US (4) US20090221544A1 (de)
EP (5) EP1868614B1 (de)
JP (5) JP5394059B2 (de)
AT (2) ATE520404T1 (de)
AU (2) AU2006226774B2 (de)
CA (2) CA2601715C (de)
CY (2) CY1111478T1 (de)
DE (1) DE602006020353D1 (de)
DK (2) DK1868614T3 (de)
ES (2) ES2392454T3 (de)
HK (3) HK1112579A1 (de)
HR (2) HRP20110198T1 (de)
PL (2) PL2030622T3 (de)
PT (2) PT2030622E (de)
RS (1) RS52471B (de)
WO (2) WO2006102644A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP1868614B1 (de) * 2005-03-24 2012-08-08 Emory University Dosierschema zur behandlung einer traumatischen gehirnverletzung mit progesteron
EP2052724A1 (de) * 2007-10-26 2009-04-29 sanofi-aventis Verwendung von Norgestimat als selektivem Hemmer der Ionenkanäle TRPC3, TRPC6 sowie TRPC6 und TRPC7
AU2009219230A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
EP2331571B1 (de) 2008-09-18 2015-08-26 Northwestern University Nmda-rezeptormodulatoren und ihre verwendung
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
ES2773079T3 (es) 2010-02-08 2020-07-09 Shenzhen Evergreen Therapeutics Co Ltd Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
SG10202010665YA (en) * 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
LT2806877T (lt) * 2012-01-23 2019-12-10 Sage Therapeutics Inc Neuroaktyvios steroidų kompozicijos, apimančios alopregnanolono ir sulfobutilo eterio beta-ciklodekstrino kompleksą
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
CN110251463A (zh) 2012-02-29 2019-09-20 贝朗医疗有限公司 含激素的乳液
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
EP2925327B1 (de) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolon zur behandlung, verminderung oder milderung von symptomen der wochenbettdepression
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
EP3978507A1 (de) 2013-08-12 2022-04-06 Emory University Progesteronphosphatanaloga und damit einhergehende verwendungen
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
EP3490990B1 (de) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spirolactam-nmda-modulatoren und verfahren zu deren verwendung
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
WO2023102149A1 (en) * 2021-12-02 2023-06-08 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ATE275957T1 (de) * 1993-01-19 2004-10-15 Endorech Inc Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
AU7569194A (en) * 1993-08-20 1995-03-21 Meyer B. Jackson Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
ES2235187T3 (es) * 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
EP0778768B1 (de) * 1995-06-09 2004-05-26 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
JP2000513336A (ja) 1996-05-22 2000-10-10 ディバーシファイド ファーマシューティカルズ，インコーポレーテッド 薬物の経皮送達のための組成物、方法及びデバイス
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
EP0981349B1 (de) 1997-05-02 2002-11-06 Wyeth 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1868614B1 (de) * 2005-03-24 2012-08-08 Emory University Dosierschema zur behandlung einer traumatischen gehirnverletzung mit progesteron
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
DK1868614T3 (da) 2012-11-12
EP2431042B1 (de) 2013-06-26
JP5295755B2 (ja) 2013-09-18
CY1113253T1 (el) 2016-04-13
EP2030622A1 (de) 2009-03-04
CA2602950A1 (en) 2006-09-28
HK1128242A1 (en) 2009-10-23
US20120289491A1 (en) 2012-11-15
HRP20120688T1 (hr) 2012-09-30
HK1112581A1 (en) 2008-09-12
EP1871382B1 (de) 2011-08-17
PT2030622E (pt) 2011-06-02
CY1111478T1 (el) 2015-08-05
JP2013234191A (ja) 2013-11-21
HK1112579A1 (en) 2008-09-12
EP1868614A2 (de) 2007-12-26
WO2006102644A2 (en) 2006-09-28
JP5496407B2 (ja) 2014-05-21
RS52471B (en) 2013-02-28
PL1868614T3 (pl) 2013-01-31
EP2494976A1 (de) 2012-09-05
US20090325920A1 (en) 2009-12-31
DE602006020353D1 (de) 2011-04-07
AU2006226811B2 (en) 2010-11-25
CA2601715C (en) 2012-10-16
ES2428313T3 (es) 2013-11-07
EP2030622B1 (de) 2011-02-23
EP1868614B1 (de) 2012-08-08
AU2006226774B2 (en) 2010-12-02
WO2006102596A2 (en) 2006-09-28
JP2008534512A (ja) 2008-08-28
DK2030622T3 (da) 2011-05-02
JP2011225629A (ja) 2011-11-10
ES2392454T3 (es) 2012-12-10
AU2006226774A1 (en) 2006-09-28
AU2006226811A1 (en) 2006-09-28
WO2006102596A3 (en) 2007-01-18
CA2602950C (en) 2012-10-30
ATE520404T1 (de) 2011-09-15
JP5394059B2 (ja) 2014-01-22
JP2008534515A (ja) 2008-08-28
EP2431042A1 (de) 2012-03-21
US20090221544A1 (en) 2009-09-03
JP2014055183A (ja) 2014-03-27
US20120245133A1 (en) 2012-09-27
WO2006102644A3 (en) 2007-03-01
PL2030622T3 (pl) 2011-07-29
WO2006102644A9 (en) 2006-11-23
PT1868614E (pt) 2012-11-23
US8614203B2 (en) 2013-12-24
CA2601715A1 (en) 2006-09-28
EP1871382A2 (de) 2008-01-02
ATE499104T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
HRP20110198T1 (hr) Indikacija doziranja progesterona u liječenju traumatske ozljede mozga
HRP20161284T1 (hr) METODE LIJEČENJA MULTIPLOG MIJELOMA KORIŠTENJEM KOMBINIRANIH TERAPIJA TEMELJENIH NA HuLuc63 S BORTEZOMIBOM
HRP20170868T1 (hr) Liječenje alergije na kikiriki
RU2013108248A (ru) Иммуногенные противовоспалительные композиции
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
MA30290B1 (fr) Therapie antitumorale a l'aide d'un anticorps contre le facteur de croissance endotheliale vasculaire et d'un anticorps contre le recepteur du facteur de croissance epitheliale humain de type 2
WO2007059342A3 (en) Random copolymer compositions for treating unwanted immune response
RU2014141180A (ru) Новое лечение острого лимфобластного лейкоза у детей
WO2007078443A3 (en) Methods of treating unwanted immune response with random copolymers
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
MX354371B (es) Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales.
TW200724135A (en) Asymmetric dosing methods
HRP20120228T1 (hr) Kladribinski režim za liječenje multiple skleroze
Tripuwabhrut et al. Experimental orthodontic tooth movement and extensive root resorption: periodontal and pulpal changes
WO2005120542A3 (en) Methods of treating disease with random copolymers
RU2006132069A (ru) Противораковые терапии
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
JP2015500822A5 (de)
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
JP2009539916A5 (de)
CA2435921A1 (en) Method of cancer therapy
JP2009538916A5 (de)